Trial Outcomes & Findings for POWER (Pulse Width Optimized Waveform Evaluation Trial) (NCT NCT00311181)

NCT ID: NCT00311181

Last Updated: 2019-02-20

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

217 participants

Primary outcome timeframe

Implant

Results posted on

2019-02-20

Participant Flow

Participant milestones

Participant milestones
Measure
Group 1
Overall Study
STARTED
217
Overall Study
COMPLETED
121
Overall Study
NOT COMPLETED
96

Reasons for withdrawal

Reasons for withdrawal
Measure
Group 1
Overall Study
Final DFTs were not obtained
96

Baseline Characteristics

POWER (Pulse Width Optimized Waveform Evaluation Trial)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group 1
n=217 Participants
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
88 Participants
n=5 Participants
Age, Categorical
>=65 years
129 Participants
n=5 Participants
Age, Continuous
67 years
STANDARD_DEVIATION 14 • n=5 Participants
Sex: Female, Male
Female
57 Participants
n=5 Participants
Sex: Female, Male
Male
160 Participants
n=5 Participants
Region of Enrollment
United States
217 participants
n=5 Participants

PRIMARY outcome

Timeframe: Implant

Outcome measures

Outcome measures
Measure
Group 1
n=121 Participants
Defibrillation Thresholds (DFTs) (3.5 ms Waveform)
427 Volts
Standard Error 11

PRIMARY outcome

Timeframe: Implant

Outcome measures

Outcome measures
Measure
Group 1
n=121 Participants
DFT (2.5 ms Waveform)
454 Volts
Standard Error 11

PRIMARY outcome

Timeframe: Implant

Outcome measures

Outcome measures
Measure
Group 1
n=121 Participants
DFT (4.5 ms Waveform)
435 Volts
Standard Error 11

Adverse Events

Group 1

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Ashish Oza

St Jude Medical

Phone: 818-493-3648

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place